Financial PerformanceTopline grew 102% in 3Q24, with total revenue of $0.7M, indicating strong growth potential for IceCure Medical.
Market ExpansionRecent clinical and commercial momentum within key markets, including the US, Europe, and Japan, indicates increasing awareness and adoption of ProSense for the treatment of breast cancer and other indications.
Regulatory ApprovalThe FDA Medical Device Advisory Committee Panel gave a favorable recommendation for ICCM's ProSense System, indicating that the benefits outweigh the risks.